tirzepatide to retatrutide vs. Tirzepatide: The New Contender vs. the Current Leader Retatrutide vs tirzepatide dosage chart:

Nat ImmunolDelaying pyroptosis with an AI-screened gasdermin D pore blocker mitigates inflammatory response

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in patients with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity, and since 2024 for cardiovascular risk reduction in patients with established cardiovascular disease and overweight or obesity

Recent reports of intestinal blockages have prompted the FDA to add a warning label on Ozempic, even though similar warnings are already present on Mounjaro and Wegovy

The safety profile was evaluated by the attending physician during a follow-up visit based on an interview with the patient